<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5F44D980-91F5-4741-B8D1-6E7FB9183303"><gtr:id>5F44D980-91F5-4741-B8D1-6E7FB9183303</gtr:id><gtr:name>Fudan University</gtr:name><gtr:address><gtr:line1>670 Guoshun Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AB871950-0395-4429-A864-DBE2C1F8A574"><gtr:id>AB871950-0395-4429-A864-DBE2C1F8A574</gtr:id><gtr:name>University of Cyprus</gtr:name><gtr:address><gtr:line1>75 Kallipoleos Street</gtr:line1><gtr:line2>PO BOX 20537</gtr:line2><gtr:line3>1678, Nicosia</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5F44D980-91F5-4741-B8D1-6E7FB9183303"><gtr:id>5F44D980-91F5-4741-B8D1-6E7FB9183303</gtr:id><gtr:name>Fudan University</gtr:name><gtr:address><gtr:line1>670 Guoshun Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB871950-0395-4429-A864-DBE2C1F8A574"><gtr:id>AB871950-0395-4429-A864-DBE2C1F8A574</gtr:id><gtr:name>University of Cyprus</gtr:name><gtr:address><gtr:line1>75 Kallipoleos Street</gtr:line1><gtr:line2>PO BOX 20537</gtr:line2><gtr:line3>1678, Nicosia</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/40F92293-6DA4-49EA-80F7-7A7B11EF92F7"><gtr:id>40F92293-6DA4-49EA-80F7-7A7B11EF92F7</gtr:id><gtr:firstName>Daniel</gtr:firstName><gtr:surname>Gale</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0600420"><gtr:id>16FF008A-6341-45A4-B303-B8D054400761</gtr:id><gtr:title>Familial erythrocytosis and altered oxygen sensing - a genetic and clinical investigation.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0600420</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Central to the cellular response to hypoxia is the von Hippel-Lindau (VHL) - hypoxia-inducible factor (HIF) pathway. Studies of patients with inherited abnormalities of this pathway (eg Von Hippel Lindau disease and Chuvash polycythaemia) have given insights into the role that these proteins play in oxygen sensing and the cellular response to hypoxia.

Physiological studies of patients with Chuvash polycythaemia have demonstrated highly abnormal cardiopulmonary physiology with abnormally elevated basal pulmonary vascular tone and an exaggerated response to hypoxia. The VHL-HIF system has been implicated in hypoxia regulation in many different tissues and it may be that a deeper understanding of this system would open avenues of treatment for conditions as diverse as cancer, acute tubular necrosis, pulmonary hypertension and the anaemia of renal failure.

A family has been identified in which raised erythropoietin levels have been found in association with polycythaemia, implicating an abnormality in an upstream regulator of erythropoietin expression. The index case has subsequently developed clinically significant pulmonary hypertension and the pedigree contains 7 informative meioses. Investigations have not demonstrated a functionally significant mutation in VHL or PHD 2 (the only two genes known to be associated with hereditary erythrocytosis and elevated erythropoietin levels). It seems likely that a novel mutation in one of the components of the VHL-HIF system is responsible. 

The aim of this proposal is to determine which gene is responsible and characterise the genetic, molecular, cellular, haematological and cardiopulmonary abnormalities in order to provide further insights into the oxygen sensing system, and particularly to understand why these patients do not have a predisposition to cancer.

In order to investigate this, the following investigations will be performed:
1. Identify the gene responsible and investigate mechanism of action of the altered protein.
2. Characterise the clinical phenotype of these patients with echocardiography, abdominal ultrasound imaging and measurement of circulating proteins (including VEGF, ferritin and urinary hepcidin) which may be affected by altered HIF activity.
3. Perform cell based assays to determine how peripheral blood lymphocytes from these patients respond to different oxygen tensions.
4. Investigate cardiopulmonary physiology in this pedigree and compare it to Chuvash patients and controls.
5. Investigate iron handling and erythropoiesis in PHD knockout mice.</gtr:technicalSummary><gtr:fund><gtr:end>2009-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>284227</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Renal Medicine</gtr:department><gtr:description>Hepcidin in humans</gtr:description><gtr:id>4A68332A-02C1-4961-89DA-2D4DA3D3A911</gtr:id><gtr:impact>Publications reported in section 1: 19839227 19833632 19212416</gtr:impact><gtr:outcomeId>77836417FA7-1</gtr:outcomeId><gtr:partnerContribution>Provided infrastructure for clinical studiesAssay development and validation necessary for clinical studies</gtr:partnerContribution><gtr:piContribution>Identification of patient groups to study; study design; sample collection; data analysis; writing paper</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cyprus</gtr:collaboratingOrganisation><gtr:country>Cyprus, Republic of</gtr:country><gtr:department>Molecular Medicine Research Center</gtr:department><gtr:description>Investigation of CFHR5</gtr:description><gtr:id>C5E8A809-EE4C-4730-8521-94DFD3432E26</gtr:id><gtr:impact>Helped secure further funding for the project.</gtr:impact><gtr:outcomeId>sLK3LzdB2Rm-1</gtr:outcomeId><gtr:partnerContribution>Has allowed access to clinicians, patients and expertise from Cyprus for the study of CFHR5 nephropathy</gtr:partnerContribution><gtr:piContribution>Identification of a newly recognised genetic cause of renal failure which is endemic in Cyprus.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fudan University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Nephrology</gtr:department><gtr:description>Genetics of IgA nephropathy</gtr:description><gtr:id>D213AA4A-EB78-49CC-BC9D-A669E9639A67</gtr:id><gtr:impact>Publication in seciton 1: PMID 20031928</gtr:impact><gtr:outcomeId>ha2d2qssKsf-1</gtr:outcomeId><gtr:partnerContribution>Assembly of DNA databank.</gtr:partnerContribution><gtr:piContribution>SNP genotyping and statistical analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Section of Endocrinology and Investigative Medicine</gtr:department><gtr:description>Hepcidin in humans</gtr:description><gtr:id>07527809-5916-4BE8-82F4-0CCB5FF426E1</gtr:id><gtr:impact>Publications reported in section 1: 19839227 19833632 19212416</gtr:impact><gtr:outcomeId>77836417FA7-2</gtr:outcomeId><gtr:partnerContribution>Provided infrastructure for clinical studiesAssay development and validation necessary for clinical studies</gtr:partnerContribution><gtr:piContribution>Identification of patient groups to study; study design; sample collection; data analysis; writing paper</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Starter Grant for Clinical Lecturers</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Academy of Medical Sciences (AMS)</gtr:fundingOrg><gtr:id>A964C4A6-3130-4C1B-942A-BAC1B17F283D</gtr:id><gtr:outcomeId>ESxAMkASiUS0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1022548</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinician Scientist Award</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G1002528</gtr:fundingRef><gtr:id>72000A58-9CF8-42FA-8033-8E75FA326535</gtr:id><gtr:outcomeId>FeNRZLkwHNH0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>St Peter's Trust for Kidney, Bladder and Prostate Research</gtr:fundingOrg><gtr:id>CF708F14-15E6-4E5E-B16A-FB26DE9D29A5</gtr:id><gtr:outcomeId>015E7539AF40</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>125000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GIKD Research Grant</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Rosetrees Trust</gtr:fundingOrg><gtr:fundingRef>M260-CD1</gtr:fundingRef><gtr:id>8566AC5D-4B0B-449B-8E7B-363F75C48E25</gtr:id><gtr:outcomeId>fprZvHw19bd</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MCKD Research Grant</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>Rosetrees Trust</gtr:fundingOrg><gtr:id>C356A7F7-3F91-4A3A-B8A9-4D32E135B3BE</gtr:id><gtr:outcomeId>U4zHgzXa18d0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Research Training Fellowship (2006)</gtr:description><gtr:end>2009-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0600420</gtr:fundingRef><gtr:id>9C45D1CB-C822-4B8D-878B-75746004E3DB</gtr:id><gtr:outcomeId>713D50C5C9F0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Mutation of the CFHR5 gene lead to complement activation in, and damage to, the kidney. The invention is a method to use changes in CFHR5 (either protein levels or protein sequence) to diagnose kidney disease or risk of kidney disease, and to use the CFHR5 protein (or part of it) as a way of treating kidney disease</gtr:description><gtr:grantRef>G0600420</gtr:grantRef><gtr:id>C32DBAB1-6AAF-4EA4-95A0-905FF417ECF0</gtr:id><gtr:impact>Clinical screening for changes in CFHR5 are now standard care for some kidney diseases in which complement is activated in the kidney.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>JZCM8aY7gBz</gtr:outcomeId><gtr:patentId>WO2011004148</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Methods relating to a mutation in complement factor H-related 5 in patients with glomerulonephritis</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>The clinical genetic test for CFHR5 nephropathy is now in use in clinical genetic laboratories in the UK and Cyprus. Its invention and development was funded by and MRC research grant.</gtr:description><gtr:id>DEA82E3F-1912-4717-AE1A-330E1434E142</gtr:id><gtr:impact>This test has provided a firm diagnosis for over 100 patients with otherwise unexplained kidney disease worldwide, obviating the need for kidney biopsy in some of these people.</gtr:impact><gtr:outcomeId>sRXStixu6UK</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Genetic test for CFHR5 nephropathy</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3BD9D1AA-C020-4A5F-8E18-7641E6673C98</gtr:id><gtr:title>Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f42c1b97115ddb10c4f209c1762ba18"><gtr:id>4f42c1b97115ddb10c4f209c1762ba18</gtr:id><gtr:otherNames>Ashby DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>pm_14077_17_19833632</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C46F7A5C-B447-4C1E-B7D6-5F6D1B0D198E</gtr:id><gtr:title>Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85c5abe4453271914e4bb8815c9c1c50"><gtr:id>85c5abe4453271914e4bb8815c9c1c50</gtr:id><gtr:otherNames>Gale DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_14077_27_20800271</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CACAEDC7-E783-4629-A754-AB7FABD73695</gtr:id><gtr:title>Variation in IGHMBP2 is not associated with IgA nephropathy in independent studies of UK Caucasian and Chinese Han patients.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61b13591a94dd0c91a537024cdaa211b"><gtr:id>61b13591a94dd0c91a537024cdaa211b</gtr:id><gtr:otherNames>Lou T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>pm_14077_27_20031928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94DAED5E-780A-4C93-B358-E9F942906D2B</gtr:id><gtr:title>Development of a novel immunoassay for the iron regulatory peptide hepcidin.</gtr:title><gtr:parentPublicationTitle>British journal of biomedical science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08e2372dd147e440d73a62589a27b2d3"><gtr:id>08e2372dd147e440d73a62589a27b2d3</gtr:id><gtr:otherNames>Busbridge M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0967-4845</gtr:issn><gtr:outcomeId>pm_14077_17_19839227</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5F359E3-4276-4C10-8D15-DE7B23A6295F</gtr:id><gtr:title>Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: von Hippel-Lindau disease and HIF-2alpha gain-of-function mutation.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f407406d5e2ef145bcece9418cbda5b"><gtr:id>7f407406d5e2ef145bcece9418cbda5b</gtr:id><gtr:otherNames>Formenti F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>pm_14077_27_21389259</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCF00269-8803-45A9-AD04-C4953F051768</gtr:id><gtr:title>Genetic loci influencing kidney function and chronic kidney disease.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6331e598a783832f88337f69a52dc44"><gtr:id>a6331e598a783832f88337f69a52dc44</gtr:id><gtr:otherNames>Chambers JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>pm_14077_27_20383145</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24A516F6-A33A-40C1-9736-FE5403C9BA8A</gtr:id><gtr:title>Dysregulation of the HIF pathway due to VHL mutation causing severe erythrocytosis and pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4de781fcec363ef270f7c97aa412cc5"><gtr:id>f4de781fcec363ef270f7c97aa412cc5</gtr:id><gtr:otherNames>Bond J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_14077_27_21454469</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E0F4285-4D53-4566-8B13-68789CF2814E</gtr:id><gtr:title>Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f42c1b97115ddb10c4f209c1762ba18"><gtr:id>4f42c1b97115ddb10c4f209c1762ba18</gtr:id><gtr:otherNames>Ashby DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>pm_14077_17_19212416</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>929EC8E0-AE0B-41A5-93E4-FE19F4F15DD3</gtr:id><gtr:title>HLA has strongest association with IgA nephropathy in genome-wide analysis.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85563b5e25ea85e042b549cd4f0ed45a"><gtr:id>85563b5e25ea85e042b549cd4f0ed45a</gtr:id><gtr:otherNames>Feehally J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>pm_14077_27_20595679</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA4AF963-5B8E-4977-8389-FA69E4DB3C93</gtr:id><gtr:title>The role of HIF in immunity.</gtr:title><gtr:parentPublicationTitle>The international journal of biochemistry &amp; cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85c5abe4453271914e4bb8815c9c1c50"><gtr:id>85c5abe4453271914e4bb8815c9c1c50</gtr:id><gtr:otherNames>Gale DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1357-2725</gtr:issn><gtr:outcomeId>pm_14077_17_19840863</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECCDBF63-536A-431C-A166-3D047141CD99</gtr:id><gtr:title>Recurrence of complement factor H-related protein 5 nephropathy in a renal transplant.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0543b55a55c3d2a92ceedbecc7ab2059"><gtr:id>0543b55a55c3d2a92ceedbecc7ab2059</gtr:id><gtr:otherNames>Vernon KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>pm_14077_27_21114651</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9746B3CC-F46C-4EDC-BB61-90AC4490D7FF</gtr:id><gtr:title>The identification of CFHR5 nephropathy.</gtr:title><gtr:parentPublicationTitle>Journal of the Royal Society of Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85c5abe4453271914e4bb8815c9c1c50"><gtr:id>85c5abe4453271914e4bb8815c9c1c50</gtr:id><gtr:otherNames>Gale DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0141-0768</gtr:issn><gtr:outcomeId>pm_14077_27_21558096</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E14FA69-DEEE-46CE-96D5-E90B5CA025A9</gtr:id><gtr:title>Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees.</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16ca1496e4af247f777e55418c3b723a"><gtr:id>16ca1496e4af247f777e55418c3b723a</gtr:id><gtr:otherNames>Athanasiou Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn><gtr:outcomeId>pm_14077_27_21566112</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66A24897-F1D1-47FD-A9CA-9227808C46C1</gtr:id><gtr:title>Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85c5abe4453271914e4bb8815c9c1c50"><gtr:id>85c5abe4453271914e4bb8815c9c1c50</gtr:id><gtr:otherNames>Gale DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_14077_17_18650473</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4519BB10-AFAC-484F-83AA-21597610F4AC</gtr:id><gtr:title>Evidence for a lack of a direct transcriptional suppression of the iron regulatory peptide hepcidin by hypoxia-inducible factors.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39ef14f2d39997b5970bf3d35b4736dd"><gtr:id>39ef14f2d39997b5970bf3d35b4736dd</gtr:id><gtr:otherNames>Volke M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>538A719D020</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0600420</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>78FE8F42-8AFB-48F8-8662-37D541AD95BF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Congenital Disorders</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>